Drug Information

General Information
Drug ID
DR00272
Drug Name
Bumetanide
Synonyms
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid; Aquazone; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; B 3023; Bumedyl; Bumetanida; Bumetanida [INN-Spanish]; Bumetanide (JP15/USP); Bumetanide (JP15/USP/INN); Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Bumetanide [USAN:BAN:INN:JAN]; Bumetanidum; Bumetanidum [INN-Latin]; Bumethanide; Bumex; Bumex (TN); Bumex, Bumetanide; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Farmacusi Brand of Bumetanide; Fontego; Fordiuran; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Lixil; Lixil-Leo; Lunetoron; Miccil; PF 1593; PF-1593; PF1593; Ro 10-6338; Ro-10-6338; Roche Brand of Bumetanide; Segurex; Senosiain Brand of Bumetanide; Yurinex
Drug Type
Small molecular drug
Indication Edema associated with congestive heart failure [ICD11: BD10] Approved [1]
Therapeutic Class
Diuretics
Structure
3D MOL 2D MOL
Formula
C17H20N2O5S
Canonical SMILES
CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
InChIKey
MAEIEVLCKWDQJH-UHFFFAOYSA-N
CAS Number
CAS 28395-03-1
Pharmaceutical Properties Molecular Weight 364.4 Topological Polar Surface Area 127
Heavy Atom Count 25 Rotatable Bond Count 8
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 7
XLogP
2.8
PubChem CID
2471
PubChem SID
10321639 , 11110843 , 11110844 , 11120301 , 11120789 , 11121277 , 11121573 , 11122053 , 11335209 , 11360448 , 11362642 , 11364211 , 11365204 , 11366773 , 11367766 , 11369335 , 11370555 , 11370556 , 11372660 , 11373367 , 11373578 , 11375928 , 11377497 , 11461420 , 11466304 , 11467424 , 11484716 , 11486107 , 11488866 , 11491296 , 11491845 , 11495131 , 14852701 , 17404725 , 24278265 , 26612248 , 26680422 , 26746951 , 26746952 , 26751481 , 26758346 , 29221635 , 46508147 , 4652638 , 47216571 , 47440017 , 7847313 , 8149787 , 8151648 , 855675
ChEBI ID
CHEBI:3213
TTD Drug ID
D0R7HO
DT(s) Transporting This Drug MCT6 Transporter Info Monocarboxylate transporter 6 Substrate [2]
NCC Transporter Info Thiazide-sensitive sodium-chloride cotransporter Substrate [3]
OAT2 Transporter Info Organic anion transporter 2 Substrate [4]
OAT3 Transporter Info Organic anion transporter 3 Substrate [5]
OAT4 Transporter Info Organic anion transporter 4 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OAT2 Transporter Info Km = 7.52 microM Oocytes-OAT2 [4]
OAT3 Transporter Info Km = 1586 microM Proximal tubule (S2) cells-OAT3 [5]
OAT4 Transporter Info Km = 306 microM Proximal tubule (S2) cells-OAT4 [5]
References
1 Bumetanide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
3 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
4 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
5 Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.